We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




POC Molecular TB Test Could Enable Clinicians to Begin Appropriate Treatment Immediately

By HospiMedica International staff writers
Posted on 15 Dec 2022
Print article
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)

According to the World Health Organization’s 2022 Global Tuberculosis Report, the difference in the number of people who were infected with tuberculosis (TB) and the number of people diagnosed with TB widened in both 2020 and 2021 versus 2019 to over four million each year. To address this crisis, a substantial new supply of molecular TB tests is required. However, existing options are limited by price, test run time, electricity requirements as well as a reliance on a sputum sample type, which can be challenging to collect from many patients. Now, a new molecular TB testing system currently under development aims to provide highly accurate results at a low price at the point of care, enabling clinicians to immediately commence appropriate treatment and patient management to maximize health outcomes and minimize further spread of infection.

LumiraDx (London, UK) is developing a point of care molecular TB test to be used with the LumiraDx multi-assay platform. The LumiraDx platform is designed to run a variety of sample types and technology with 12 tests currently available. The TB test is the first molecular test the company has developed for the point of care platform. LumiraDx’s actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need.

The LumiraDx molecular TB test is designed to fill the gaps and needs in the TB testing market and significantly increase access to testing. The TB testing system is being developed to provide testing at a lower cost and incorporate a tongue swab sample which makes it easier for a higher percentage of patients to be tested. In addition, the portability of the LumiraDx Platform, which weighs only 1.1kg, and uses a rechargeable battery, would allow the TB test to be used in decentralized settings across low and middle-income countries where lab access is limited. The LumiraDx Platform is the only point of care instrument that supports both molecular and immunoassay technologies.

“The advancement of our TB molecular test signifies an important step forward in LumiraDx’s mission to increase access to accurate and affordable testing worldwide as well as an important step forward in our molecular testing technology,” said Ron Zwanziger, LumiraDx CEO.

Related Links:
LumiraDx

New
Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
New
Medical Software
Bladder Scanner Graphics Workstation Software
New
Data Management Platform
Track-it
New
X-Ray Image Acquisition Software
dicomPACS DX-R

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Critical Care

view channel
Image: The new biomaterial heals tissues from the inside out (Photo courtesy of UC San Diego)

Groundbreaking Biomaterial Injected Intravenously Repairs Cells and Tissue Damaged by Heart Attack and TBI

Following a heart attack, there is development of scar tissue, which affects muscle function and can result in congestive heart failure. However, there is still no established treatment available for repairing... Read more

Surgical Techniques

view channel
Image: The neuro-chip with soft implantable electrodes could manage brain disorders (Photo courtesy of EPFL)

Implantable Neuro-Chip Uses Machine Learning Algorithm to Detect and Treat Neurological Disorders

Using a combination of low-power chip design, machine learning algorithms, and soft implantable electrodes, researchers have produced a neural interface that can identify and suppress symptoms of different... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.